Table 1 EC50 of DT2216, Bcl-2 family protein inhibitors, or chemotherapy drugs against selective T cell lymphoma (TCL) cell lines
From: DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
TCL cell lines | Chemotherapy drugs (nM) | Bcl-2 family inhibitors (μM) | DT2216 (μM) | |||||
|---|---|---|---|---|---|---|---|---|
Doxorubicin | Etoposide | Vincristine | ABT263 | A-1155463 | ABT199 | S63845 | (a selective Bcl-xL | |
(Bcl-2/xL) | (Bcl-xL) | (Bcl-2) | (Mcl-1) | degrader) | ||||
MyLa (CTCL) | 124.60 | 199.50 | 8.60 | 0.04 | 0.0008 | > 5 | > 5 | 0.005 |
MJ (CTCL) | 480 | > 10,000 | 60 | 0.33 | 0.30 | > 10 | > 10 | 0.10 |
MAC2A (ALK-ALCL) | 120 | 1260 | < 1 | 0.06 | 0.009 | 1.80 | > 10 | 0.28 |
L82 (ALK+ALCL) | 30 | 110 | < 1 | 0.07 | 0.03 | 2.38 | 1.55 | 0.02 |
DL40 (ALK-ALCL) | 10 | 80 | < 1 | 4.42 | > 10 | > 10 | 0.003 | > 10 |
SMZ1 (PTCL-NOS) | 10 | 100 | 1.50 | 9.71 | > 10 | > 10 | 0.05 | > 10 |
FEPD (ALK-ALCL) | 60 | 370 | 10 | 7.90 | > 10 | 8.99 | 0.22 | > 10 |
Human PLT | – | – | – | 0.13 | – | – | – | > 10 |